Risk factors
Puma Biotechnology (PBYI) risk factors
Item 1A of every Puma Biotechnology, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors63 risks2 dropped8 reworded
Puma Biotechnology relies heavily on five major customers representing 74% of revenue, faces pricing pressures from healthcare reform and the One Big Beautiful Bill Act, and maintains an accumulated deficit of $1,283.8 million alongside $97.5 million in cash.
Filed Feb 26, 2026 - FY2024 10-K risk factors65 risks
Puma Biotechnology depends heavily on sales of its single commercial product, NERLYNX, and development of its pipeline candidate alisertib. The company faces significant customer concentration, debt covenant restrictions, and reliance on third-party manufacturers and international sub-licensees.
Filed Feb 27, 2025